231 related articles for article (PubMed ID: 21419185)
1. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Lorenc-Koci E; Lenda T; Antkiewicz-Michaluk L; Wardas J; Domin H; Smiałowska M; Konieczny J
Neurochem Int; 2011 Jun; 58(7):839-49. PubMed ID: 21419185
[TBL] [Abstract][Full Text] [Related]
2. Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Konieczny J; Lenda T; Czarnecka A
Neuroscience; 2016 Jun; 324():92-106. PubMed ID: 26964686
[TBL] [Abstract][Full Text] [Related]
3. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
[TBL] [Abstract][Full Text] [Related]
4. Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry.
Mackey S; Jing Y; Flores J; Dinelle K; Doudet DJ
Exp Neurol; 2013 Sep; 247():19-24. PubMed ID: 23557600
[TBL] [Abstract][Full Text] [Related]
5. The influence of acute and chronic administration of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline on the function of the nigrostriatal dopaminergic system in rats.
Lorenc-Koci E; Antkiewicz-Michaluk L; Kamińska A; Lenda T; Zieba B; Wierońska J; Smiałowska M; Schulze G; Rommelspacher H
Neuroscience; 2008 Oct; 156(4):973-86. PubMed ID: 18809471
[TBL] [Abstract][Full Text] [Related]
6. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
7. Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
Konieczny J; Jantas D; Lenda T; Domin H; Czarnecka A; Kuter K; Śmiałowska M; Lasoń W; Lorenc-Koci E
Neurotox Res; 2014 Oct; 26(3):255-73. PubMed ID: 24842651
[TBL] [Abstract][Full Text] [Related]
8. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Harrison IF; Anis HK; Dexter DT
Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
[TBL] [Abstract][Full Text] [Related]
9. Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system.
Lorenc-Koci E; Antkiewicz-Michaluk L; Wardas J; Zapała M; Wierońska J
Brain Res; 2004 May; 1009(1-2):67-81. PubMed ID: 15120584
[TBL] [Abstract][Full Text] [Related]
10. The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Antkiewicz-Michaluk L
Neuroscience; 2017 Jan; 340():308-318. PubMed ID: 27826109
[TBL] [Abstract][Full Text] [Related]
11. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
[TBL] [Abstract][Full Text] [Related]
12. The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain.
Wąsik A; Romańska I; Zelek-Molik A; Nalepa I; Antkiewicz-Michaluk L
Neurotox Res; 2018 Oct; 34(3):706-716. PubMed ID: 30129004
[TBL] [Abstract][Full Text] [Related]
13. Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.
Deneyer L; Albertini G; Bentea E; Massie A
Parkinsonism Relat Disord; 2019 Nov; 68():26-32. PubMed ID: 31621614
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.
Ichitani Y; Okamura H; Nakahara D; Nagatsu I; Ibata Y
Exp Neurol; 1994 Dec; 130(2):269-78. PubMed ID: 7867756
[TBL] [Abstract][Full Text] [Related]
15. [Sleep changes during degeneration of neurons in the substantia nigra induced by inhibitor of proteasomes lactacystin in rats].
Pastukhov IuF; Chesnokova AIu; Iakimchuk AA; Ekimova IV; Romanova IV; Khudik KA
Ross Fiziol Zh Im I M Sechenova; 2010 Dec; 96(12):1190-202. PubMed ID: 21473106
[TBL] [Abstract][Full Text] [Related]
16. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration.
Zhu W; Li X; Xie W; Luo F; Kaur D; Andersen JK; Jankovic J; Le W
Neurobiol Dis; 2010 Feb; 37(2):307-13. PubMed ID: 19818853
[TBL] [Abstract][Full Text] [Related]
17. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
18. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
20. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
